Novavax Signs License and Option Agreement With Pfizer
Less than 1 min read
Novavax entered into a License and Option Agreement with Pfizer to grant a non-exclusive, worldwide license to its Matrix-M adjuvant technology for use in vaccines across up to two infectious disease fields. Pfizer will control development, manufacturing, and commercialization, with Novavax to supply the adjuvant under contemplated supply agreements. Novavax will receive a $30 million upfront payment in Q1 2026, up to $500 million in development and sales milestones, and tiered high mid-single digit royalties on net sales. Pfizer may add a second disease field later, subject to certain limitations.
Agreement details:
- Agreement type: Non-exclusive worldwide license and option for Matrix-M adjuvant technology
- Counterparty: Pfizer
- Signed / Effective: Jan 15 2026 / Jan 15 2026
- Duration / Termination: Long-term; royalties until later of 20 years or patent expiry
- Reason: Expand Matrix-M adoption and monetize through milestones and royalties
Original SEC Filing: NOVAVAX INC [ NVAX ] - 8-K - Jan. 20, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.